Publication

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Related publications (35)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

Graph Chatbot

Chat with Graph Search

Targeting BCR-ABL and JAK2 in Ph+ ALL

NUP214-ABL1 mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility

Safe Implementation of Embedded Software for a Portable Device Supporting Drug Administration

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions

TAT-based Formal Representation of Medical Guidelines : Imatinib Case-study

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis